Provider Resources to Support Patients

Optimizing PARP Inhibitor Therapy in Veterans With Prostate Cancer: A Practical Guide for VA Pharmacists

This event, brought to you by PeerView Live and ZERO Prostate Cancer, features experts Brooke Looney, PharmD, CSP and Izabela Mazur, PharmD, BCOP providing insight on the latest evidence on use of PARP inhibition in the treatment of mCRPC and practical guidance on genomic testing, patient education, and team-based toxicity management delivered via realistic patient case discussions. Join this virtual learning opportunity originally presented at the 2024 Joint Federal Pharmacy Seminar. This activity will expire on December 10, 2025.

Nurse-Led Strategies for Optimizing PARP Inhibitors in Veterans With Prostate Cancer: Genomic Testing and Practical Care Delivery

This event from ZERO and PeerView was held during the 2024 Nurses Organization of Veterans Affairs Conference. Experts Kassandra August-Marcucio, DNP, APRN, ACNP-BC, SANE and Grace Cullen, DNP, FNP-BC, AOCNP, PMGT-BC, FPCN discussed genomic testing recommendations and nurse-led strategies to optimize the use of PARP inhibitors in veterans with prostate cancer. This activity will expire on November 29, 2025.

Unlocking the Power of Modern Therapeutic Regimens for Prostate Cancer: Experts Put the Pressure on Key Evidence and Real-World Strategies to Optimize Patient Care

In this educational activity, a panel of experts competes to answer questions on prostate cancer treatment and provide updates on the latest practice-changing data on neoadjuvant, adjuvant, and radioligand immunotherapy in prostate cancer along with an expert-led discussion of the implications for practice. Featuring Karim Fizazi, MD, PhD, Pedro C. Barata, MD, MSc, FACP, Kim N. Chi, MD, FRCPC, and Alicia K. Morgans, MD, MPH, this event was held live at ASCO 2024 in partnership with PeerView. This activity will expire on July 1, 2025.

Advanced Prostate Cancer: Personalized Treatment Plan

Join Shawn Dason, MD; Dakim Gaines, MD, PhD; and Andrew Laccetti, MD, MS to learn about integrating the latest clinical insights into monotherapy and combination treatments for advanced prostate cancer. Hone your skills in developing personalized treatment plans for a diverse range of patients and settings, while integrating a multidisciplinary approach. This activity was developed through a partnership with MedAll. The recording will be active until June 5, 2025.

Advanced Prostate Cancer: Latest Clinical Trials to Treatment Plans

Join Shawn Dason, MD; Dakim Gaines, MD, PhD; and Andrew Laccetti, MD, MS to discover emerging treatments from clinical trials and learn to integrate them into current protocols, enhancing your everyday practice with evidence-based advancements. This activity was developed through a partnership with MedAll. The recording will be active until June 5, 2025.

Treatment Advances and Individualized Therapeutic Strategies in Prostate Cancer: Expert Insights on Key Evidence, Practical Tips for Personalized Therapy, and Clinical Integration Approaches

How are treatment advances in prostate cancer providing new options to individualize therapeutic strategies in a variety of settings? In a new video-based CME activity from PeerView and ZERO, Alicia K. Morgans, MD, MPH, and Neal D. Shore, MD, FACS, discuss evidence supporting the use of treatment intensification, radioligands, PARP inhibitors, and immunotherapy and provide tips for improving care for patients with localized disease, biochemical recurrence, mHSPC, and mCRPC. This activity will expire on April 24, 2025.

Doing Better Under Pressure In Prostate Cancer: Key Evidence and Real-World Care Strategies

A panel of experts, including Robert Dreicer, MD, MS, MACP, FASCO, Alicia K. Morgans, MD, MPH, Neal D. Shore, MD, FACS, and Matthew R. Smith, MD, PhD, compete to answer questions on prostate cancer treatment while providing insight on evidence supporting the use of a variety of therapeutics and strategies for personalized treatment selection, including genetic and molecular testing, and increasing access to optimal care! Originally presented at ASCO GU 2024 and available virtually, this session is brought to you by PeerView and ZERO. This activity will expire on February 25, 2025.

Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum

Given the range of effective options and more on the horizon, how do clinicians ensure that the right patients receive the right treatments? Join Neal D. Shore, MD, FACS; Alicia K. Morgans, MD, MPH; Ashley E. Ross, MD, PhD; and Matthew R. Smith, MD, PhD to get answers to your questions on prostate cancer treatment in an engaging new activity brought to you by PeerView and ZERO that combines expert-led mini-lectures with fast-paced quiz segments designed to reinforce key concepts. This activity will expire on December 31, 2024.

Use of PARP Inhibitor Plus AR-Signaling Inhibitor Combinations for Patients with mCRPC: A medical oncologist's perspective

In this expert commentary, Rana R. McKay, MD, offers her perspective on how the latest approvals of combination therapy with a PARP inhibitor and an AR-signaling inhibitor will affect treatment choices for patients with mCRPC. Provided by Clinical Care Options, LLC., in partnership with ZERO.

Nursing Support for mCRPC patients during radiopharmaceutical treatment

In this video update, Uro-oncology Clinical Nurse Specialist Janet Forgenie explains how nurses can support patients undergoing radiopharmaceutical treatment for metastatic castrate-resistant prostate cancer (mCRPC). Watch the video and download the accompanying slides to learn about: a) the considerations for treatment selection in clinical practice to minimize the impact on patients' lives; b) applying recent data to treatment sequencing in bone-dominant mCRPC; and c) educating and supporting patients during treatment so they know what to expect Provided by COR2ED, in partnership with ZERO.

Treatment intensification in mCSPC: The nurse perspective

In this podcast, oncology nurses Brenda Martone and Jennifer Sutton discuss how to use data to select the most appropriate treatments for patients with metastatic castration-sensitive prostate cancer. They also share the importance of being able to explain these clinical decisions to patients and reassure them that earlier intensive treatment can prolong overall survival without seriously impacting quality of life. Provided by COR2ED, in partnership with ZERO.

Podcast: Which mCSPC patients benefit from early treatment intensification?

In this podcast, you'll hear Dr. Shilpa Gupta, MD and Dr. Fabio Schutz review patient cases to explore which patients with metastatic castration-sensitive prostate cancer (mCSPC) benefit from early treatment intensification. They discuss how to apply key data from ARASENS and PEACE-1 in clinical practice, triplet therapy as the new standard of care, and the patient subgroups that benefit the most from early treatment intensification. Provided by COR2ED, in partnership with ZERO.

The Role of the Nurse in nmCRPC Patient Management

In this video, Research Nurse Coordinator Pablo Peinado discusses selecting treatments for nmCRPC in clinical practice to minimize the impact on the patient's quality of life, and how nurses can support and educate their patients, so they know what to expect during treatment. Provided by COR2ED, in partnership with ZERO.

The Prostate Cancer Clinical Masterclass Series

The Prostate Cancer Clinical Masterclass Series is a free, on-demand education series for clinicians, co-chaired by Dr. Sumit Subudhi and Dr. Gert Attard. It boasts a faculty of 24 guest presenters who are leading clinicians within the global prostate cancer space. This twelve-month initiative consists of monthly episodes which are led by two guest presenters, who will each deliver a fifteen-minute presentation, followed by a group discussion with the co-chairs.

The purpose of published guidelines are to provide providers and patients with evidence-based and consensus-based best practices for diagnosing, treating, and managing prostate cancer. The American Urologic Association publishes healthcare provider guidelines for early detection, localized prostate cancer, advanced prostate cancer, and radiotherapy.

In addition, the National Comprehensive Cancer Network (NCCN) Guidelines document evidence-based, consensus-driven management to ensure that all patients receive preventive, diagnostic, treatment, and supportive services that are most likely to lead to optimal outcomes. Patient guidelines are also available through the NCCN.